1031431-96-5

Basic information

• Product Name: N-ETHYL-N'-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2-PYRIDINYL]-UREA
• Synonyms: N-ETHYL-N'-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2-PYRIDINYL]-UREA;1-ethyl-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)urea
• CAS NO: 1031431-96-5
• Molecular Weight: 291.15378
• Mol File: 1031431-96-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-ETHYL-N'-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2-PYRIDINYL]-UREA(CAS DataBase Reference)
• NIST Chemistry Reference: N-ETHYL-N'-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2-PYRIDINYL]-UREA(1031431-96-5)
• EPA Substance Registry System: N-ETHYL-N'-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2-PYRIDINYL]-UREA(1031431-96-5)

Safety Data

• Hazardous Substances Data: 1031431-96-5(Hazardous Substances Data)

Upstream product

• 827614-64-2 2-aminopyridine-5-boronic acid pinacol ester 
• 109-90-0 ethyl isocyanate 

Downstream Products

• 1031428-45-1 methyl 4-(6-{[(ethylamino)carbonyl]amino}pyridin-3-yl)benzoate 
• 1031428-43-9 methyl 3-(6-{[(ethylamino)carbonyl]amino}pyridin-3-yl)benzoate 
• 1031428-78-0 4-(6-{[(ethylamino)carbonyl]amino}pyridin-3-yl)benzoic acid 
• 1031428-75-7 3-(6-{[(ethylamino)carbonyl]amino}pyridin-3-yl)benzoic acid 
• 1031432-32-2 2-(6-{[(ethylamino)carbonyl]amino}pyridin-3-yl)-N-(1-methyl-1-phenylethyl)-1,3-benzothiazole-7-carboxamide 
• 1031431-98-7 2-(6-{[(Ethylamino)carbonyl]amino}pyridin-3-yl)-N-(1-methyl-1-phenylethyl)-1,3-thiazole-5-carboxamide 

Relevant articles and documents

Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents

The discovery and optimization of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain are described. A fragment molecule, 1-ethyl-3-(2-pyridyl)urea, provided sufficiently potent enzyme inhibition (

CHEMICAL COMPOUNDS

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also desc